Halo's scientific platform in extracellular matrix biology has the potential to support a robust pipeline of multiple indications and therapeutic modalities.

To operate in a capital efficient manner, the company  maintains a primary focus on its lead program, H1614, a small-molecule first-in-class inhibitor of hyaluronan (HA) synthesis for pulmonary hypertension and interstitial lung disease (PH-ILD).   H1614 is a proprietary reformulation of 4-methylumbelliferone (4-MU) which is ready for clinical study in 2026.

The company also secured FDA orphan drug designation (ODD) for 4-MU in the indication of primary sclerosing cholangitis and has established an earlier stage pipeline strategy for the development of new proprietary assets.